Key result
Oral administration of the novel curcumin analog Y20 at 20 mg/kg significantly decreased cardiac inflammation and oxidative stress, and improved cardiac remodeling in high-fat diet-fed obese rats.
Why the study?
Does the novel curcumin analog Y20 mitigate cardiac injury in high fat diet-induced obese rats?
Does the novel curcumin analog Y20 mitigate cardiac injury in high fat diet-induced obese rats?
Answers are grounded in this paper and cite their sources.
The novel curcumin analog Y20 attenuates obesity-induced cardiac remodeling, inflammation, and oxidative stress in rats, highlighting its potential as a therapeutic agent for obesity cardiomyopathy.
Obesity is strongly associated with the cause of structural and functional changes of the heart in both human and animal models. Oxidative stress and inflammation play a critical role in the development of obesity-induced cardiac disorders. Curcumin is a natural product from Curcuma Longa with multiple bioactivities. In our previous study, in order to reach better anti-inflammatory and anti-oxidant dual activities, we designed a new mono-carbonyl curcumin analog, Y20, via the structural modification with both trifluoromethyl and bromine. This study was designed to investigate the protective effects of Y20 on obesity-induced cardiac injury and its underlying mechanisms. In high fat diet-fed rats, oral administration of Y20 at 20 mg/kg or curcumin at 50 mg/kg significantly decreased the cardiac inflammation and oxidative stress and eventually improved the cardiac remodeling by mitigating cardiac disorganization, hypertrophy, fibrosis and apoptosis. Y20 at 20 mg/kg showed comparable and even stronger bioactivities than curcumin at 50 mg/kg. The beneficial actions of Y20 are closely associated with its ability to increase Nrf2 expression and inhibit NF-κB activation. Taken together, these results suggest that Y20 may have a great therapeutic potential in the treatment of obesity-induced cardiac injury using Nrf2 and NF-κB as the therapeutic targets for treating obesity-related disorders.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2015) studied Obesity-induced cardiac injury (n=24). Y20 vs. Vehicle (HFD only) and Curcumin (50 mg/kg/day) was evaluated on Cardiac inflammation, oxidative stress, and cardiac remodeling (p=<0.05). Oral administration of the novel curcumin analog Y20 at 20 mg/kg significantly decreased cardiac inflammation and oxidative stress, and improved cardiac remodeling in high-fat diet-fed obese rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: